Bionomics announces Australia Supreme Court approves re-domiciliation

Bionomics (BNOX) announced that the Supreme Court of New South Wales, Australia has made orders approving the scheme of arrangement in relation to the company’s proposed re-domiciliation from Australia to the United States, under which Neuphoria Therapeutics, will become the ultimate parent company of Bionomics Limited following the implementation of the scheme. A copy of the court’s orders with respect to the Scheme was lodged with the Australian Securities & Investments Commission following the Court hearing, at which time the Scheme became legally effective. Bionomics’ ADSs will continue to trade on Nasdaq until the implementation date. Bionomics shareholders who hold shares on the record date for the scheme. The scheme consideration will be paid to scheme shareholders on the implementation date. Shares of Neuphoria are expected to begin trading on Nasdaq under the symbol (NEUP) on December 24 or as soon as possible thereafter.